Aranesp Phase II Heart Failure Data Suggest Benefit; Phase III Underway
This article was originally published in The Pink Sheet Daily
Amgen presents data from a pooled analysis of two randomized Phase II trials in heart failure patients with anemia.
You may also be interested in...
Deal could be worth more than $725 million.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter